Related Experiment Videos
Retinoids and mammary gland differentiation
Ciba Foundation Symposium
|January 1, 1985
Summary
Certain retinoids, like N-(4-hydroxyphenyl)retinamide (HPR), show promise as breast cancer chemopreventive agents. HPR effectively inhibits mammary gland proliferation and lesion development both in vivo and in vitro.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Retinoids are recognized for their role in cancer chemoprevention.
- Mammary gland proliferation is a key factor in breast cancer development.
Purpose of the Study:
- To investigate the chemopreventive and antiproliferative effects of N-(4-hydroxyphenyl)retinamide (HPR) on mammary gland tissue.
- To explore the mechanism of HPR action, including its metabolism and interaction with cellular components.
Main Methods:
- In vivo studies using C3H mice to assess HPR's effect on hyperplastic alveolar nodules.
- In vitro studies using mammary gland cells to evaluate HPR's inhibition of 7,12-dimethylbenz[a]anthracene-induced lesions and phorbol ester promotion.
- Analysis of HPR metabolism within the mammary gland and its binding to cytosolic retinoic acid-binding protein.
Main Results:
- HPR demonstrated significant inhibition of hyperplastic alveolar nodules in vivo.
- HPR effectively inhibited chemically induced mammary lesions and lesion promotion in vitro.
- HPR undergoes metabolism in the mammary gland, producing a metabolite that competes with retinoic acid for binding proteins.
Conclusions:
- N-(4-hydroxyphenyl)retinamide (HPR) is a potent chemopreventive and antiproliferative agent for the mammary gland.
- HPR's mechanism involves inhibiting lesion development and interacting with cellular retinoic acid-binding pathways.
- Further research into HPR and its metabolites could lead to novel breast cancer prevention strategies.